Russia approves second COVID-19 vaccine before completing Phase 3 trials
- 4 years ago
러시아 자체 개발 코로나19 두번째 백신도 공식 승인
Russia has approved yet another COVID-19 vaccine for public use before completing Phase 3 trials, making it its own second vaccine.
In televised comments Wednesday, Russian President Vladimir Putin said the country needs to increase production of the first and second vaccines, noting the priority is to supply the Russian market with both.
Developed by the Vector Institute in Siberia, the peptide-based, two-shot vaccine, EpiVacCorona, was tested among 100 volunteers aged between 18 and 60 years old.
But skepticism lingers as Russia's first vaccine was also approved before testing was fully complete.
Russia has approved yet another COVID-19 vaccine for public use before completing Phase 3 trials, making it its own second vaccine.
In televised comments Wednesday, Russian President Vladimir Putin said the country needs to increase production of the first and second vaccines, noting the priority is to supply the Russian market with both.
Developed by the Vector Institute in Siberia, the peptide-based, two-shot vaccine, EpiVacCorona, was tested among 100 volunteers aged between 18 and 60 years old.
But skepticism lingers as Russia's first vaccine was also approved before testing was fully complete.